BioCentury
ARTICLE | Finance

Ebb & Flow

December 7, 2009 8:00 AM UTC

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus.

Indeed, if all goes well, the company won't need the cash to pay for its $400 million in convertible debt, which is well in the money...